Drug Trial Radar · NCT05319314
LYL273 for Patients With Relapsed or Refractory mCRC
Last checked: Nov 19, 2026Latest source record: Oct 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
155
Planned (sponsor's estimate)
Start
Aug 1, 2022
Primary completion
Jun 2028
Study completion Jun 2032
Sponsor
- Lead sponsor
- Lyell Immunopharma, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 open-label, multicenter study evaluating the safety and efficacy of LYL273 in participants with relapsed or refractory metastatic colorectal cancer.
Conditions
- Colorectal Cancer
Interventions
LYL273Drug
Single infusion of Chimeric Antigen Receptor (CAR) transduced autologous T cells administered intravenously (i.v.)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 1: Incidence of adverse events (AEs) defined as dose-limiting toxicities (DLTs) during 3+3 dose escalation studyTime frame: Infusion (Day 0) to Day 28
- Phase 1: Maximum tolerable dose (MTD) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation studyTime frame: Infusion (Day 0) to Day 28
- Phase 1: Recommended Phase 2 dose (RP2D) based on incidence of dose-limiting toxicities (DLTs) during 3+3 dose escalation studyTime frame: Infusion (Day 0) to Day 28
- Phase 2: Estimate the efficacy of LYL273, as measured by overall response rate (ORR) based on Independent Review Committee (IRC) assessment per Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 criteriaTime frame: Baseline to Month 18
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
City of Hope Comprehensive Cancer Center
Duarte, California · Recruiting
University of California San Francisco Medical Center
San Francisco, California · Recruiting
University of Colorado Hospital - Anschutz Cancer Pavilion
Aurora, Colorado · Recruiting
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
SCRI Oncology Partners and Tristar Centennial Hospital
Nashville, Tennessee · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.